A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- Acronyms FLUENT
- Sponsors Novartis Pharmaceuticals
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 Planned primary completion date changed from 15 Dec 2018 to 30 Jun 2019.
- 24 Aug 2017 New trial record